Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper

dc.contributor.authorSalman, Jasim Mohammed
dc.contributor.authorAl-Dabal, Laila Mohamed
dc.contributor.authorBassetti, Matteo
dc.contributor.authorAlfouzan, Wadha Ahmed
dc.contributor.authorAl-Maslamani, Muna A.Rahman S.
dc.contributor.authorAlraddadi, B.
dc.contributor.authorElhoufi, Ashraf Mahmoud
dc.contributor.authorEnani, Mushira Abdulaziz S.
dc.contributor.authorKhamis, Faryal Ali
dc.contributor.authorMokkadas, Eiman
dc.contributor.authorRomany, Ingy
dc.contributor.authorSomily, A. M.
dc.contributor.authorKanj, Souha S.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:56:35Z
dc.date.available2025-01-24T11:56:35Z
dc.date.issued2020
dc.description.abstractAntimicrobial resistance is an important global issue that impacts the efficacy of established antimicrobial therapy. This is true globally and within the Arab countries of the Middle East, where a range of key Gram-negative pathogens pose challenges to effective therapy. There is a need to establish effective treatment recommendations for this region given specific challenges to antimicrobial therapy, including variations in the availability of antimicrobials, infrastructure and specialist expertise. This consensus provides regional recommendations for the first-line treatment of hospitalized patients with serious infections caused by World Health Organization critical priority Gram-negative pathogens Acinetobacter baumannii and Pseudomonas aeruginosa resistant to carbapenems, and Enterobacteriaceae resistant to carbapenems and third-generation cephalosporins. A working group comprising experts in infectious disease across the region was assembled to review contemporary literature and provide additional consensus on the treatment of key pathogens. Detailed therapeutic recommendations are formulated for these pathogens with a focus on bacteraemia, nosocomial pneumonia, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. First-line treatment options are provided, along with alternative agents that may be used where variations in antimicrobial availability exist or where local preferences and resistance patterns should be considered. These recommendations take into consideration the diverse social and healthcare structures of the Arab countries of the Middle East, meeting a need that is not filled by international guidelines. There is a need for these recommendations to be updated continually to reflect changes in antimicrobial resistance in the region, as well as drug availability and emerging data from clinical trials. © 2020 The Authors
dc.identifier.doihttps://doi.org/10.1016/j.ijantimicag.2020.106104
dc.identifier.eid2-s2.0-85089863122
dc.identifier.pmid32721603
dc.identifier.urihttp://hdl.handle.net/10938/31258
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Journal of Antimicrobial Agents
dc.sourceScopus
dc.subjectAcinetobacter spp
dc.subjectEnterobacteriaceae
dc.subjectGram-negative bacterial infection
dc.subjectMulti-drug resistance
dc.subjectPseudomonas spp
dc.subjectAcinetobacter baumannii
dc.subjectAnti-bacterial agents
dc.subjectAntimicrobial stewardship
dc.subjectBacteremia
dc.subjectCarbapenem-resistant enterobacteriaceae
dc.subjectConsensus development conferences as topic
dc.subjectCross infection
dc.subjectDrug resistance, multiple, bacterial
dc.subjectGram-negative bacterial infections
dc.subjectHumans
dc.subjectIntraabdominal infections
dc.subjectMiddle east
dc.subjectPneumonia, bacterial
dc.subjectPseudomonas aeruginosa
dc.subjectSoft tissue infections
dc.subjectUrinary tract infections
dc.subjectAmikacin
dc.subjectAminoglycoside
dc.subjectAvibactam plus ceftazidime
dc.subjectAztreonam
dc.subjectCarbapenem
dc.subjectCeftolozane plus tazobactam
dc.subjectCiprofloxacin
dc.subjectColistin
dc.subjectCotrimoxazole
dc.subjectDoripenem
dc.subjectDoxycycline
dc.subjectErtapenem
dc.subjectFosfomycin
dc.subjectGentamicin
dc.subjectImipenem
dc.subjectLevofloxacin
dc.subjectMeropenem
dc.subjectMinocycline
dc.subjectPiperacillin plus tazobactam
dc.subjectPlazomicin
dc.subjectPolymyxin b
dc.subjectQuinolone
dc.subjectRifampicin
dc.subjectSultamicillin
dc.subjectTigecycline
dc.subjectTobramycin
dc.subjectAntiinfective agent
dc.subjectAcinetobacter infection
dc.subjectAntibiotic therapy
dc.subjectBacterium culture
dc.subjectBroth dilution
dc.subjectDrug megadose
dc.subjectDrug monitoring
dc.subjectEnterobacteriaceae infection
dc.subjectGenotyping technique
dc.subjectHospital acquired pneumonia
dc.subjectHospital patient
dc.subjectHuman
dc.subjectImmunoaffinity chromatography
dc.subjectLoading drug dose
dc.subjectMonotherapy
dc.subjectPriority journal
dc.subjectPseudomonas infection
dc.subjectReview
dc.subjectSkin and soft tissue infection
dc.subjectSkin infection
dc.subjectSoft tissue infection
dc.subjectSystematic review
dc.subjectUrinary tract infection
dc.subjectWorld health organization
dc.subjectAbdominal infection
dc.subjectBacterial pneumonia
dc.subjectConsensus development
dc.subjectDrug effect
dc.subjectGram negative infection
dc.subjectMicrobiology
dc.subjectMultidrug resistance
dc.titleManagement of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-6514.pdf
Size:
931.03 KB
Format:
Adobe Portable Document Format